• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
OMass CEO Ros Deegan
Biotech

OMass’ $310M raise fuels goal to become ‘Britain’s Big Biotech’

OMass CEO Ros Deegan's ambition for the small-molecule biotech hasn't dimmed since Fierce last caught up with her two years ago.
James Waldron Oct 15, 2026 2:00am
iRegene Therapeuticss NouvSight001 Cleared for Clinical Trials in the US and China for Retinitis Pigmentosa

iRegene Therapeutics’s NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa

Brought to you by iRegene Therapeutics
AZ

AstraZeneca, insitro ink $1.5B AI-enabled target discovery deal

Oct 15, 2026 6:00am
A ballpoint pen rests on top of a stack of documents ready for signing

Rebranded Galapagos finally finds buyer for cell therapies

Oct 15, 2026 4:09am
IPO

Iambic goes public with $150M IPO to accelerate cancer pipeline

Oct 15, 2026 2:30am
Monumental Sports  Entertainment Vanda Pharmaceuticals studio

Vanda pauses social anxiety program after failing phase 3 trial

Oct 15, 2026 2:25am
More News

IQVIA, Veeva expand partnership for speedier clinical trials

Oct 14, 2026 2:00pm

Merck KGaA spinout iOnctura touts PI3K inhibitor in eye cancer

Oct 14, 2026 1:42pm

Verastem CEO says RAS drug 'set new benchmark' for tricky cancer

Oct 14, 2026 10:27am

Verdiva axes GLP-1 switching trial over ‘market evolution’

Oct 14, 2026 10:13am
See more stories
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings